NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS Alpha Natural ( ANR) rated new Buy at Sterne Agee ANR was initiated with a Buy rating, Sterne Agee said. $35 price target. Company remains leveraged to growth in the met coal market. Apple ( AAPL) estimates, target increased at Morgan Stanley. AAPL estimates were raised through 2013. iPhone continues to drive growth. Overweight rating and new $480 price target. Apple estimates increased at UBS. AAPL estimates raised through 2013. iPhone purchase and carrier launch delays ahead of 4S cause shortfall. Maintain $510 price target and Buy rating. Arch Coal ( ACI) rated new Neutral at Sterne Agee. $23 price target. Company faces integration challenges. Bank of America ( BAC) estimates lowered at Sterne Agee. BAC estimates were cut through 2013. Company will take a while to turn its business around. Neutral rating and $7 price target. Bank of America numbers lowered at UBS. Shares of BAC now seen reaching $7. Estimates also lowered on weaker capital markets and lower reserve releases. Neutral rating. Chipotle Mexican Grill ( CMG) rated new Neutral at UBS. $345 price target. Solid near term outlook, but appears appropriately valued. Citrix Systems ( CTXS) upgraded at Needham from Hold to Buy. $85 price target. Spending on data center projects should remain strong. Coca-Cola ( KO) estimates lowered at Credit Suisse through 2013. Currency changes are cutting into earnings. Outperform rating and $95 price target. Coca-Cola numbers lowered at UBS. Shares of KO now seen reaching $73. Estimates also lowered on currency and spending impact. Maintain Buy rating. Cree ( CREE) estimates, target reduced at Sterne Agee. Shares of CREE now seen reaching $52. Estimates also cut, to match the company's new guidance. Buy rating. Cree estimates, target lowered at UBS. Shares of CREE now seen reaching $29.50. Estimates also lowered as outlook suggest industry is still bottoming. Neutral rating. EMC ( EMC) estimates upped at Sterne Agee through 2012. Company is gaining market share and realizing higher margins. Buy rating and $30 price target. Forest Laboratories ( FRX) numbers reduced at Goldman. Shares of FRX now seen reaching $30. Estimates also cut, given the company's negative operating leverage. Forest Labs estimates, target cut at UBS. Shares of FRX now seen reaching $32. Estimates also lowered on below guidance launches. Neutral rating.